Dr. Reddy's Laboratories Ltd Q1FY22 consolidated PAT at Rs. 380.4 Cr

The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.

Dr. Reddy's launches Toripalimab in India

The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Informa Markets in India set to host 17th edition of CPHI & PMEC India Expo

CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof

Dr. Reddy's receives positive CHMP opinion from EMA for its proposed Rituximab biosimilar

Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance

Dr. Reddy's signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan

Dr. Reddy's Laboratories launches Doxycycline Capsules, 40 mg in US

ORACEA is a trademark of Galderma Holdings, S.A.

Dr. Reddy's and Nestle India to form JV for health science nutraceutical portfolio

The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios

Dr. Reddy's launches drug-free migraine management device Nerivio in Europe

Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India

Vericiguat works on a pathway not currently targeted by existing heart failure treatments

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India

Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U